Introduction
The boundary between consumer wellness wearables and regulated medical devices is no longer theoretical. It is being reshaped in real time by investment decisions, engineering trade‑offs, and the limits of physics and chemistry.
Smart rings, wristbands, and watches now provide continuous insight into heart rate, sleep, and activity. At the same time, there is growing pressure to extend these platforms beyond wellness metrics and into true biochemical monitoring, particularly glucose.
A single question dominates almost every discussion in this space:
If we can measure oxygen non‑invasively, why can’t we measure glucose the same way?
This article explains why that question is deceptively complex, why optical glucose monitoring has proven so difficult, and why solid microneedle biosensors represent a credible and scalable route toward the convergence of wellness monitoring and medical‑grade sensing.
The Current Wearable Landscape: PPG at the Core
Most mainstream wellness wearables are built on a common optical technique: photoplethysmography (PPG).
Using green LEDs (typically around 530 nm), PPG systems detect pulsatile changes in blood volume. From this signal, devices infer:
- Heart rate
- Inter‑beat interval (IBI)
- Heart‑rate variability
- Sleep and recovery metrics
Whether it is a smartwatch, smart ring, or fitness band, the underlying principle is largely the same.
⚙️ Key observation: many of today’s “different” wellness devices are, at their core, variations of the same PPG technology.
From PPG to SpO₂: Why Oxygen Works
Pulse oximetry (SpO₂) extends PPG by using two wavelengths:
- 660 nm (red) for deoxygenated haemoglobin
- 940 nm (near‑infrared) for oxygenated haemoglobin
Crucially, SpO₂ does not measure oxygen directly. It measures the ratio of oxygenated to deoxygenated haemoglobin.
This relative measurement approach has several advantages:
- ✅ Built‑in calibration through ratios
- ✅ Resistance to baseline drift
- ✅ Operation within optical “windows” where water is relatively transparent
📌 The largest constituent of blood is water, and SpO₂ happens to operate in spectral regions where water absorption is low.
Why Glucose Is Fundamentally Different
Relative vs Absolute Measurement
SpO₂ benefits from being a relative signal. Even if the absolute signal drifts, the ratio between peaks and baselines remains meaningful.
Glucose monitoring is different.
Glucose requires absolute concentration values, typically expressed in mg/dL (for example, 45–360 mg/dL in clinical use). Any drift in the sensing system directly translates into error.
✅ Oxygen tolerates relative estimation
🚫 Glucose does not
The Chemistry Problem: Concentration
From a molecular standpoint:
| Substance | Approximate concentration in blood |
|---|---|
| Water | ~55 mol/L |
| Glucose | ~5 mmol/L |
That is a ratio of approximately 11,000 water molecules for every glucose molecule.
The Physics Problem: Optical Absorption
In the mid‑infrared region often proposed for glucose sensing:
- Water absorbs infrared photons ~2,000× more efficiently than glucose
- Combined with concentration disparity, the result is a signal‑to‑noise ratio of roughly 1:22 million
🔬 In practical terms, glucose becomes a needle hidden within an extremely dense haystack of interfering signals.
Why Mid‑Infrared Spectroscopy Remains Elusive
Mid‑infrared spectroscopy does show glucose absorption features, including distinctive fingerprint regions. However:
- Water absorbs strongly in the same region
- Many organic molecules share overlapping spectral features
- The human body contains hundreds of such interfering compounds
Even when spectral “dips” exist, isolating glucose reliably under real‑world conditions remains extraordinarily difficult.
💡 This explains why non‑invasive optical glucose monitoring has remained a long‑running research programme rather than a commercial reality.
What the Industry Is Signalling
Despite these challenges, industry activity is accelerating:
- Wellness companies integrating blood tests and physician access
- Medical device companies investing in consumer wearables
- Technology platforms positioning themselves closer to healthcare delivery
This is not speculation — it reflects board‑level strategic decisions.
✅ The convergence between wellness monitoring and medical technology is already underway.
The Practical Shift: Access the Right Fluid Instead
Rather than attempting to “see” glucose through tissue, an alternative approach is to access interstitial fluid directly.
This is where solid microneedles become significant.
Why Solid Microneedles Matter
Solid microneedles provide shallow, controlled access to interstitial fluid while remaining compatible with wearable form factors.
Key Advantages
✅ Shallow insertion (≤ 2 mm)
- Avoids nerve bundles
- Minimises pain and discomfort
✅ No applicators required
- Reduced psychological and mechanical friction
- More suitable for consumer adoption
✅ Electrochemical sensing
- Absolute concentration measurement
- Established CGM principles
✅ Wearable‑friendly formats
- Wrist‑based or patch‑like designs become feasible
📌 In contrast, traditional CGMs rely on deeper transdermal filaments and spring‑loaded applicators, which can limit broader consumer acceptance.
Demonstrated System Architecture
A modern microneedle‑based glucose monitoring system typically integrates:
- Functionalised solid microneedle electrodes
- Low‑power wireless potentiostat electronics
- Bluetooth connectivity to a mobile application
- Cloud‑based data aggregation and analysis
This architecture enables:
- Continuous glucose tracking
- Clear step responses across concentrations
- Secure transmission and visualisation of data
For scalable biosensor data handling and analysis, cloud platforms such as Djuli are designed to support multi‑device workflows:
https://djuli.zimmerpeacock.no/
Why Applicators Are a Hidden Adoption Barrier
Current market‑leading CGMs are clinically effective, but they rely on:
- Transdermal filaments (~7 mm insertion)
- Single‑use applicators
- Arm‑mounted patches
While acceptable for diabetes management, these features introduce friction for mass‑market wellness adoption.
💡 Microneedles remove this barrier by design.
Where This Leaves the Industry
The competitive landscape now presents an interesting asymmetry:
- Medical device companies moving toward consumer wellness
- Technology companies moving toward regulated healthcare
Ultimately, success will depend less on brand size and more on engineering choices that scale comfortably, safely, and credibly.
From a sensing perspective, solid microneedles currently offer the most practical bridge between:
- Continuous biochemical accuracy
- Consumer‑acceptable wearables
- Future clinician‑integrated healthcare models
Practical Takeaways
✅ Measuring oxygen does not imply glucose can be measured optically
✅ Optical glucose sensing faces fundamental physics and chemistry limits
✅ Relative signals work for SpO₂; glucose requires absolute accuracy
✅ Solid microneedles bypass optical signal‑to‑noise constraints
✅ Shallow microneedles reduce pain and adoption friction
✅ Wearable CGM is most realistic via electrochemistry, not optics alone
Closing Thoughts
The convergence of wellness monitoring and medical‑grade biosensing is no longer hypothetical. It is being shaped right now by hard technical realities and pragmatic design decisions.
While non‑invasive optical glucose sensing remains an ambitious goal, solid microneedle electrochemical systems provide a grounded, scalable path forward — one that aligns with both consumer expectations and clinical requirements.
If you are exploring biosensor development, microneedle platforms, or connected electrochemical systems, collaborative discussion is often the most productive next step.